



Dedicated To Life

June 23, 2023

BSE Limited 1 st Floor, P J Towers, Dalal Street, Mumbai-400001	Code: 532321	National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051
--	---------------------	---

Sub: Acquisition of equity stake in Mylab Discovery Solutions Private Limited

Ref.: Disclosure under regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015

Dear Sir/Madam,

Pursuant to and in compliance with the provisions of regulation 30 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Zydus Animal Health and Investments Limited ("**Z AHL**"), a wholly owned subsidiary company of Zydus Lifesciences Limited ("**Company**") has entered into a Share Purchase Agreement ("**SPA**" or "**Agreement**") with Rising Sun Holdings Private Limited ("**Seller**") and Mylab Discovery Solutions Private Limited ("**Mylab**" or "**Target**") to acquire 65,06,500 (Sixty Five Lacs Six Thousand Five Hundred) equity shares having face value of Re. 1/- (Rupee One only) each (which are fully paid-up) at an agreed consideration of Rs. 106 Crores (Rupees One Hundred and Six Crore only) representing 6.5% of the total paid-up equity share capital of Mylab from the Seller. The ultimate number of shares to be held can change, as per the terms of the Agreement, based on the financial performance of Mylab for the year ending on March 31, 2024.

Requisite disclosure as required under the SEBI Circular dated September 9, 2015 is enclosed as **Annexure-I**.

Please take the above information on record.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above





Dedicated To Life

Annexure-I

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	<p>Name of the target entity: Mylab Discovery Solutions Private Limited (“Mylab” or “Target”)</p> <p>Brief Details: Mylab is engaged in the business of researching, developing, manufacturing, marketing and selling in-vitro diagnostics kits, equipment, reagents and related therapeutic products that are linked to its diagnostic portfolio and providing portfolio solutions to other labs and hospitals.</p> <p>Turnover: Rs. 95 Crore (Rupees Ninety-Five Crores only) for the year ended March 31, 2023, based on provisional financial statements.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	<p>The proposed acquisition of equity shares does not fall within the purview of related party transactions.</p> <p>None of the promoter/ promoter group has any interest in the entity.</p>
c)	Industry to which the entity being acquired belongs;	Healthcare Solutions.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The proposed investment in Mylab will help the company to participate in growing diagnostics space which is expected to witness increased penetration through in-clinic solutions with Point of Care Testing (“POCT”) devices.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable





Dedicated To Life

Sr. No.	Particulars	Details
f)	Indicative time-period for completion of the acquisition;	Two months from the date of signing the SPA for acquisition of 65,06,500 equity shares of Mylab from the existing shareholder.
g)	Nature of consideration-whether cash consideration or share swap and details of the same;	Cash consideration.
h)	Cost of acquisition or the price at which the shares are acquired	Rs. 106 Crores (Rupees One Hundred and Six Crores only).
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	65,06,500 equity shares of Re. 1/- each representing 6.5% of the total paid-up share capital of Mylab.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Background: Mylab is engaged in the business of researching, developing, manufacturing, marketing and selling in-vitro diagnostics kits, equipment, reagents and related therapeutic products that are linked to its diagnostic portfolio and providing portfolio solutions to other labs and hospitals.</p> <p>History of last 3 years' turnover:</p> <ul style="list-style-type: none">• For the year ended March 31, 2021: Rs. 825 Crore• For the year ended March 31, 2022: Rs. 260 Crore• For the year ended March 31, 2023: Rs. 95 Crore, based on provisional financial statements. <p>(Note: The turnover of Mylab for the years ended March 31, 2021 and March 31, 2022 also included sales of Covid self-testing kits)</p> <p>Country: India</p>

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

